Why is the Ramsay (ASX:RHC) share price so volatile today?

COVID is hitting Ramsay's operations…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price has pulled back from its intraday highs in afternoon trade.

At the time of writing, the private hospital operator's shares are up 0.5% to $68.00.

This compares to a 2% gain for the Ramsay share price in earlier trade.

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.

Image source: Getty Images

What did Ramsay announce?

This afternoon Ramsay released an update in relation to the impact that COVID-19 restrictions are having on its operations.

It notes that the NSW Ministry of Health will introduce restrictions on non-urgent overnight Category 2 and Category 3 elective surgeries at all private hospitals in the state effective 10 January.

Category 2 admission relates to a condition which is not likely to deteriorate quickly or become an emergency within 90 days. Whereas a Category 3 admission is unlikely to deteriorate quickly and has little potential to become an emergency within 365 days.

In addition to this, Ramsay highlights that similar changes were made by the Victorian Department of Health and Human Services (DHHS) to surgical restrictions on 6 January. Elective surgery is now restricted to urgent elective surgery procedures.

Further, neither the DHHS nor the NSW Ministry of Health have provided a date for when these restrictions will end and Ramsay will be able to return to business as usual.

What will the impact be?

Ramsay has warned that these and previous surgical restrictions will have a material impact on its earnings in FY 2022. For example, it notes that in the first quarter, COVID related disruptions and costs impacted its Australian earnings by $55 million.

And while January is the seasonally quietest month of the year in the Australian business, it remains unclear when the current wave of Omicron cases will subside and Ramsay will be able to operate as normal again. This could see the restrictions creep into busier months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »